YM Biosciences (YMI) Reports Nimotuzumab Approved For Marketing In Mexico
More News related to YMI
- YM BioSciences (YMI) Receives Two Patents for AeroLEF Acute and Severe Pain Treatment
- YM BioSciences granted two US patents for AeroLEF(R)
- YM BioSciences reports second quarter 2010 operational and financial results
- The Trout Group LLC and BioBusiness.TV Team to Produce '60 Second Pitch' Videos for Biotechnology Companies
- YM BioSciences completes merger with Cytopia
More News related to FDA
- Micromet (MITI) Outlines Clinical Plans for Blinatumomab in ALL
- Celsion Corp. (CLSN) Recommended to Continue Enrollments for ThermoDox Phase III
- Isis Pharmaceuticals (ISIS) Falls On Safety Concerns
- AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
- Curis (CRIS) Announces Publication of CUDC-101 Data
YM BioSciences Inc. (NYSE: YMI) reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC).
"Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made in its commercialization," said David Allan, Chairman and CEO of YM BioSciences. "As part of YM's registration strategy for nimotuzumab, we were also pleased to report the opening of this second of two randomized, double-blind trials that YM is conducting in Canada and which are both now being expanded internationally."
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
